706 related articles for article (PubMed ID: 34252266)
1. Pyroptosis, a new bridge to tumor immunity.
Li L; Jiang M; Qi L; Wu Y; Song D; Gan J; Li Y; Bai Y
Cancer Sci; 2021 Oct; 112(10):3979-3994. PubMed ID: 34252266
[TBL] [Abstract][Full Text] [Related]
2. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
[TBL] [Abstract][Full Text] [Related]
3. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.
Hsu SK; Li CY; Lin IL; Syue WJ; Chen YF; Cheng KC; Teng YN; Lin YH; Yen CH; Chiu CC
Theranostics; 2021; 11(18):8813-8835. PubMed ID: 34522213
[TBL] [Abstract][Full Text] [Related]
4. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
Theivanthiran B; Evans KS; DeVito NC; Plebanek M; Sturdivant M; Wachsmuth LP; Salama AK; Kang Y; Hsu D; Balko JM; Johnson DB; Starr M; Nixon AB; Holtzhausen A; Hanks BA
J Clin Invest; 2020 May; 130(5):2570-2586. PubMed ID: 32017708
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
6. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
8. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
9. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
Kalantari Khandani N; Ghahremanloo A; Hashemy SI
J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
[TBL] [Abstract][Full Text] [Related]
10. From Inflammasome to Exosome-Does Extracellular Vesicle Secretion Constitute an Inflammasome-Dependent Immune Response?
Cypryk W; Nyman TA; Matikainen S
Front Immunol; 2018; 9():2188. PubMed ID: 30319640
[TBL] [Abstract][Full Text] [Related]
11. NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer.
Faria SS; Costantini S; de Lima VCC; de Andrade VP; Rialland M; Cedric R; Budillon A; Magalhães KG
J Biomed Sci; 2021 Apr; 28(1):26. PubMed ID: 33840390
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
13. Relevance of the Pyroptosis-Related Inflammasome Pathway in the Pathogenesis of Diabetic Kidney Disease.
Liu P; Zhang Z; Li Y
Front Immunol; 2021; 12():603416. PubMed ID: 33692782
[TBL] [Abstract][Full Text] [Related]
14. NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development.
Ahechu P; Zozaya G; Martí P; Hernández-Lizoáin JL; Baixauli J; Unamuno X; Frühbeck G; Catalán V
Front Immunol; 2018; 9():2918. PubMed ID: 30619282
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
[TBL] [Abstract][Full Text] [Related]
18. Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy.
Karan D
Front Immunol; 2018; 9():3028. PubMed ID: 30631327
[TBL] [Abstract][Full Text] [Related]
19. Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis.
Wu XY; Li KT; Yang HX; Yang B; Lu X; Zhao LD; Fei YY; Chen H; Wang L; Li J; Peng LY; Zheng WJ; Hou Y; Jiang Y; Shi Q; Zhang W; Zhang FC; Zhang JM; Huang B; He W; Zhang X
J Autoimmun; 2020 Jan; 106():102336. PubMed ID: 31601476
[TBL] [Abstract][Full Text] [Related]
20. Pyroptosis: a new paradigm of cell death for fighting against cancer.
Tan Y; Chen Q; Li X; Zeng Z; Xiong W; Li G; Li X; Yang J; Xiang B; Yi M
J Exp Clin Cancer Res; 2021 May; 40(1):153. PubMed ID: 33941231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
